Form 4: Catalyst Pharma Director Sells Shares After Option Exercise

Catalyst Pharmaceuticals Director Molly Harper exercised stock options and subsequently sold a portion of the acquired shares for personal reasons, retaining 2,360 common shares.

Summary

• Molly Harper, a Director at Catalyst Pharmaceuticals, Inc. (CPRX), exercised options to acquire 20,000 shares of common stock at an exercise price of $5.78 per share on December 12, 2025.
• On the same date, Harper sold a total of 26,746 shares of common stock in multiple open market transactions.
• The sales included 15,527 shares at a weighted average price of $23.198 (ranging from $22.67 to $23.67), 4,473 shares at a weighted average price of $23.734 (ranging from $23.67 to $23.82), and 6,746 shares at $23.06.
• Following these transactions, Harper directly beneficially owns 2,360 shares of common stock.
• Harper also retains beneficial ownership of 128,497 options to purchase common stock.
• The shares were sold for personal reasons and to fund the exercise price of the stock options, explicitly stating it was not due to any disagreement with the Company.

Sentiment

Score: 6

Explanation: The director exercised options at a much lower price and sold shares, which is a common liquidity event. The explicit statement that the sale was for personal reasons and not due to disagreement with the company helps to maintain a neutral to slightly positive sentiment, as it clarifies the intent behind the sale. The director also retains a substantial number of unexercised options.

Positives

• Director Molly Harper exercised 20,000 stock options, indicating a realization of value from previously granted equity.
• The exercise price of $5.78 is significantly lower than the sale prices (ranging from $22.67 to $23.82), demonstrating a substantial gain on the exercised options.
• The director still retains 128,497 options to purchase common stock, maintaining a significant equity interest in the company's future performance.

Negatives

• Director Molly Harper sold a total of 26,746 shares, reducing her direct beneficial ownership of common stock to 2,360 shares.
• The sale represents a significant reduction in direct shareholding by a director, which could be interpreted negatively by some investors.

Future Outlook

NA

Management Comments

• Shares were sold on the open market for personal reasons and to fund the exercise price of the stock options, and not as a result of any disagreement with the Company.

Industry Context

NA

Stakeholder Impact

• Shareholders: May view the director's sale of shares as a signal, but the explanation of 'personal reasons' and 'not disagreement' aims to reassure. The reduction in direct ownership might be a minor concern.

Key Dates

Recommendation

While the director sold a significant number of shares, the transaction is primarily an option exercise and subsequent sale for personal liquidity, not necessarily a bearish signal on the company's future. The explicit statement that the sale was not due to disagreement with the company helps to mitigate negative interpretations. Given the context, a 'hold' recommendation is appropriate, suggesting investors maintain their current position while monitoring future developments and broader company performance.

Keywords

Catalyst Pharmaceuticals, CPRX, Molly Harper, Insider Trading, Form 4, Stock Options, Share Sale, Director Transaction, Beneficial Ownership